<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4182069</article-id><article-id pub-id-type="publisher-id">1129-2377-15-S1-G10</article-id><article-id pub-id-type="doi">10.1186/1129-2377-15-S1-G10</article-id><article-categories><subj-group subj-group-type="heading"><subject>Meeting Abstract</subject></subj-group></article-categories><title-group><article-title>EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Goadsby</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Dodick</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Spierings</surname><given-names>E</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Scherer</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Sweeney</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Grayzel</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib></contrib-group><aff id="I1"><label>1</label>NIHR-Wellcome Trust Clinical Research Facility (KCL) and Dept. of Neurology (UCSF), King's College London and Univ. of California - San Francisco, London, UK</aff><aff id="I2"><label>2</label>Dept. of Neurology, Mayo Clinic, Phoenix, USA</aff><aff id="I3"><label>3</label>Dept. of Neurology (BWH) and Headache &#x00026; Face Pain Program, Brigham &#x00026; Women's Hospital Harvard Medical School and Tufts School of Dental Medicine, Boston, USA</aff><aff id="I4"><label>4</label>Eli Lilly and Company (retired), Indianapolis, USA</aff><aff id="I5"><label>5</label>Arteaus Therapeutics, Cambridge, USA</aff><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>18</day><month>9</month><year>2014</year></pub-date><volume>15</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Abstracts from the 4th European Headache and Migraine Trust International Congress: EHMTIC 2014</named-content><named-content content-type="supplement-sponsor">Publication costs for this supplement were funded by the conference.</named-content></supplement><fpage>G10</fpage><lpage>G10</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Goadsby et al; licensee Springer.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Goadsby et al; licensee Springer.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.thejournalofheadacheandpain.com/content/15/S1/G10"/><conference><conf-date>18-21 September 2014</conf-date><conf-name>4th European Headache and Migraine Trust International Congress: EHMTIC 2014</conf-name><conf-loc>Copenhagen, Denmark</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Migraine remains poorly treated with few effective preventive medications available.</p></sec><sec><title>Aim</title><p>We evaluated the efficacy and safety of LY2951742, a fully humanized monoclonal antibody to Calcitonin Gene-Related Peptide (CGRP) for migraine prevention.</p></sec><sec sec-type="methods"><title>Methods</title><p>Eligible subjects with 4-14 migraine headache days (MHD) per month were randomized in a double-blind manner to LY2951742 or placebo, administered subcutaneously, every other week over a 12-week period. The primary endpoint was the mean change from baseline in number of MHD in the last 28 day period (month three); secondary end points included the mean change in headache days, migraine attacks, and the 50% responder rate at month 3.</p></sec><sec sec-type="results"><title>Results</title><p>Mean change in MHD (primary) was -4.2 vs. -3.0 for LY2951742 (n=107) and placebo (n=110), respectively (p = 0.003). LY2951742 was superior to placebo for all secondary endpoints including headache days -4.9 vs. -3.7 (p = 0.0117), migraine attacks -3.1 vs. -2.3 (p = 0.0051), and 50% responder rate, 70% vs. 45% (OR 2.88 [CI 1.78;4.69]). An exploratory endpoint of complete response (100% reduction in MHD in month 3) was 31.6% vs. 17.3% (OR 2.16 [CI 1.24;3.75]) for LY2951742 and placebo, respectively. Adverse events reported by approximately &#x02265;5% of LY2951742-treated patients and more frequently with LY2951742 than placebo included upper respiratory tract infections, injection site pain, neck pain, abdominal pain, dizziness, injection site erythema, rash, hypertension and pain in extremity.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Treatment with LY2951742 demonstrated significant separation from placebo on the primary and secondary endpoints. LY2951742 appeared to be safe and well-tolerated.</p></sec></body></article>